Viatris Inc. (VTRS)
USD 7.63
(1.19%)
USD 7.63
(1.19%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 54.7 Million USD | -97.37% |
| 2022 | 2.07 Billion USD | 263.79% |
| 2021 | -1.26 Billion USD | -89.45% |
| 2020 | -669.9 Million USD | -4087.5% |
| 2019 | 16.8 Million USD | -95.23% |
| 2018 | 352.5 Million USD | -49.35% |
| 2017 | 696 Million USD | 45.0% |
| 2016 | 480 Million USD | -43.37% |
| 2015 | 847.6 Million USD | -8.8% |
| 2014 | 929.4 Million USD | 49.01% |
| 2013 | 623.7 Million USD | -2.68% |
| 2012 | 640.85 Million USD | 19.38% |
| 2011 | 536.8 Million USD | 55.55% |
| 2010 | 345.11 Million USD | 48.39% |
| 2009 | 232.57 Million USD | 218.61% |
| 2008 | -196.07 Million USD | 87.08% |
| 2007 | -1.51 Billion USD | 0.0% |
| 2006 | 184.54 Million USD | -9.36% |
| 2005 | 184.54 Million USD | -9.36% |
| 2004 | 203.59 Million USD | -39.16% |
| 2003 | 334.6 Million USD | 0.0% |
| 2002 | 260.25 Million USD | 600.96% |
| 2001 | 37.12 Million USD | -75.93% |
| 2000 | 154.24 Million USD | 33.66% |
| 1999 | 115.4 Million USD | 14.48% |
| 1998 | 100.8 Million USD | 59.75% |
| 1997 | 63.1 Million USD | -38.32% |
| 1996 | 102.3 Million USD | -15.38% |
| 1995 | 120.9 Million USD | 65.39% |
| 1994 | 73.1 Million USD | 3.54% |
| 1993 | 70.6 Million USD | 76.06% |
| 1992 | 40.1 Million USD | 22.63% |
| 1991 | 32.7 Million USD | 24.81% |
| 1990 | 26.2 Million USD | 43.17% |
| 1989 | 18.3 Million USD | -27.38% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 113.9 Million USD | 114.88% |
| 2024 Q2 | -326.4 Million USD | -386.57% |
| 2023 Q2 | 264 Million USD | 17.49% |
| 2023 Q3 | 331.6 Million USD | 25.61% |
| 2023 Q4 | -765.6 Million USD | -330.88% |
| 2023 Q1 | 224.7 Million USD | -77.78% |
| 2023 FY | 54.7 Million USD | -97.37% |
| 2022 Q4 | 1.01 Billion USD | 185.41% |
| 2022 FY | 2.07 Billion USD | 263.79% |
| 2022 Q3 | 354.3 Million USD | 12.87% |
| 2022 Q2 | 313.9 Million USD | -21.37% |
| 2022 Q1 | 399.2 Million USD | 251.33% |
| 2021 Q4 | -263.8 Million USD | -184.69% |
| 2021 Q2 | -279.2 Million USD | 73.09% |
| 2021 Q3 | 311.5 Million USD | 211.57% |
| 2021 FY | -1.26 Billion USD | -89.45% |
| 2021 Q1 | -1.03 Billion USD | -13.3% |
| 2020 Q4 | -915.8 Million USD | -593.16% |
| 2020 Q1 | 20.8 Million USD | 1.46% |
| 2020 Q2 | 39.4 Million USD | 89.42% |
| 2020 Q3 | 185.7 Million USD | 371.32% |
| 2020 FY | -669.9 Million USD | -4087.5% |
| 2019 FY | 16.8 Million USD | -95.23% |
| 2019 Q3 | 189.8 Million USD | 212.64% |
| 2019 Q4 | 20.5 Million USD | -89.2% |
| 2019 Q1 | -25 Million USD | -148.83% |
| 2019 Q2 | -168.5 Million USD | -574.0% |
| 2018 Q4 | 51.2 Million USD | -71.02% |
| 2018 Q1 | 87.1 Million USD | -64.35% |
| 2018 FY | 352.5 Million USD | -49.35% |
| 2018 Q2 | 37.5 Million USD | -56.95% |
| 2018 Q3 | 176.7 Million USD | 371.2% |
| 2017 Q2 | 297 Million USD | 347.29% |
| 2017 Q1 | 66.4 Million USD | -84.1% |
| 2017 FY | 696 Million USD | 45.0% |
| 2017 Q3 | 88.3 Million USD | -70.27% |
| 2017 Q4 | 244.3 Million USD | 176.67% |
| 2016 Q2 | 168.4 Million USD | 1111.51% |
| 2016 Q3 | -119.8 Million USD | -171.14% |
| 2016 Q4 | 417.5 Million USD | 448.5% |
| 2016 FY | 480 Million USD | -43.37% |
| 2016 Q1 | 13.9 Million USD | -92.86% |
| 2015 Q3 | 428.6 Million USD | 155.42% |
| 2015 Q1 | 56.6 Million USD | -70.08% |
| 2015 FY | 847.6 Million USD | -8.8% |
| 2015 Q4 | 194.6 Million USD | -54.6% |
| 2015 Q2 | 167.8 Million USD | 196.47% |
| 2014 Q3 | 499.1 Million USD | 298.64% |
| 2014 Q2 | 125.2 Million USD | 8.02% |
| 2014 Q1 | 115.9 Million USD | -35.68% |
| 2014 Q4 | 189.2 Million USD | -62.09% |
| 2014 FY | 929.4 Million USD | 49.01% |
| 2013 Q3 | 158.9 Million USD | 0.0% |
| 2013 Q1 | 106.88 Million USD | -34.01% |
| 2013 Q4 | 180.2 Million USD | 13.4% |
| 2013 FY | 623.71 Million USD | -2.67% |
| 2013 Q2 | 177.68 Million USD | 66.25% |
| 2012 FY | 640.85 Million USD | 19.38% |
| 2012 Q4 | 161.96 Million USD | -23.33% |
| 2012 Q3 | 211.25 Million USD | 52.48% |
| 2012 Q2 | 138.55 Million USD | 7.34% |
| 2012 Q1 | 129.07 Million USD | -0.32% |
| 2011 Q1 | 104.17 Million USD | 424.89% |
| 2011 FY | 536.81 Million USD | 55.55% |
| 2011 Q2 | 146.44 Million USD | 40.58% |
| 2011 Q4 | 129.49 Million USD | -17.36% |
| 2011 Q3 | 156.69 Million USD | 7.0% |
| 2010 Q4 | 19.84 Million USD | -86.14% |
| 2010 Q1 | 95.85 Million USD | 146.39% |
| 2010 Q2 | 86.22 Million USD | -10.05% |
| 2010 Q3 | 143.18 Million USD | 66.05% |
| 2010 FY | 345.11 Million USD | 48.39% |
| 2009 Q3 | -5.26 Million USD | -105.67% |
| 2009 Q4 | 38.9 Million USD | 839.34% |
| 2009 Q1 | 106.05 Million USD | 2143.11% |
| 2009 FY | 232.57 Million USD | 228.34% |
| 2009 Q2 | 92.87 Million USD | -12.43% |
| 2008 Q4 | -5.19 Million USD | -102.51% |
| 2008 Q3 | 206.75 Million USD | 683.38% |
| 2008 Q1 | -409.17 Million USD | 0.0% |
| 2008 Q2 | 26.39 Million USD | 106.45% |
| 2008 FY | -181.21 Million USD | -183.4% |
| 2007 Q3 | 149.82 Million USD | 87.93% |
| 2007 Q4 | - USD | -100.0% |
| 2007 FY | 217.28 Million USD | 17.74% |
| 2007 Q1 | -71.28 Million USD | -152.63% |
| 2007 Q2 | 79.72 Million USD | 211.84% |
| 2006 Q2 | 75.58 Million USD | 31.11% |
| 2006 FY | 184.54 Million USD | -9.36% |
| 2006 Q1 | 57.65 Million USD | 19.59% |
| 2006 Q3 | 77.54 Million USD | 2.59% |
| 2006 Q4 | 135.44 Million USD | 74.68% |
| 2005 Q2 | 42.91 Million USD | 12.53% |
| 2005 Q1 | 38.13 Million USD | 9.68% |
| 2005 FY | 203.59 Million USD | -39.16% |
| 2005 Q4 | 48.2 Million USD | 34.77% |
| 2005 Q3 | 35.77 Million USD | -16.65% |
| 2004 Q2 | 82.03 Million USD | 9.6% |
| 2004 Q3 | 48.65 Million USD | -40.69% |
| 2004 Q4 | 34.77 Million USD | -28.54% |
| 2004 FY | 334.6 Million USD | 22.86% |
| 2004 Q1 | 74.85 Million USD | -11.54% |
| 2003 Q2 | 83.86 Million USD | 13.57% |
| 2003 Q1 | 73.84 Million USD | 7.91% |
| 2003 Q4 | 84.61 Million USD | -7.3% |
| 2003 FY | 272.35 Million USD | 4.65% |
| 2003 Q3 | 91.27 Million USD | 8.84% |
| 2002 FY | 260.25 Million USD | 600.96% |
| 2002 Q4 | 68.43 Million USD | 0.3% |
| 2002 Q3 | 68.22 Million USD | 10.32% |
| 2002 Q2 | 61.84 Million USD | -8.09% |
| 2002 Q1 | 67.29 Million USD | -13.92% |
| 2001 Q4 | 78.17 Million USD | 21.89% |
| 2001 Q2 | 50.64 Million USD | 20.41% |
| 2001 Q1 | 42.06 Million USD | 11.74% |
| 2001 FY | 37.12 Million USD | -75.93% |
| 2001 Q3 | 64.13 Million USD | 26.63% |
| 2000 Q1 | 44.74 Million USD | 10.76% |
| 2000 Q4 | 37.64 Million USD | 12.34% |
| 2000 Q3 | 33.5 Million USD | 144.04% |
| 2000 Q2 | -76.08 Million USD | -270.05% |
| 2000 FY | 154.24 Million USD | 33.66% |
| 1999 FY | 115.4 Million USD | 14.48% |
| 1999 Q1 | 35.8 Million USD | 336.59% |
| 1999 Q2 | 32 Million USD | -10.61% |
| 1999 Q3 | 37.1 Million USD | 15.94% |
| 1999 Q4 | 40.4 Million USD | 8.89% |
| 1998 Q2 | 34.2 Million USD | 7.55% |
| 1998 FY | 100.8 Million USD | 59.75% |
| 1998 Q3 | 37.2 Million USD | 8.77% |
| 1998 Q4 | 8.2 Million USD | -77.96% |
| 1998 Q1 | 31.8 Million USD | 44.55% |
| 1997 Q1 | 13.7 Million USD | -24.31% |
| 1997 FY | 63.1 Million USD | -38.32% |
| 1997 Q4 | 22 Million USD | -27.63% |
| 1997 Q3 | 30.4 Million USD | 83.13% |
| 1997 Q2 | 16.6 Million USD | 21.17% |
| 1996 FY | 102.3 Million USD | -15.38% |
| 1996 Q2 | 14 Million USD | -20.9% |
| 1996 Q4 | 18.1 Million USD | 4.62% |
| 1996 Q3 | 17.3 Million USD | 23.57% |
| 1996 Q1 | 17.7 Million USD | -19.18% |
| 1995 Q1 | 33.3 Million USD | 4.72% |
| 1995 FY | 120.9 Million USD | 65.39% |
| 1995 Q2 | 33.2 Million USD | -0.3% |
| 1995 Q4 | 21.9 Million USD | -25.76% |
| 1995 Q3 | 29.5 Million USD | -11.14% |
| 1994 Q4 | 31.8 Million USD | 10.8% |
| 1994 Q1 | 17.4 Million USD | -21.27% |
| 1994 Q3 | 28.7 Million USD | 5.9% |
| 1994 Q2 | 27.1 Million USD | 55.75% |
| 1994 FY | 73.1 Million USD | 3.54% |
| 1993 Q3 | 17.4 Million USD | 8.07% |
| 1993 Q4 | 22.1 Million USD | 27.01% |
| 1993 FY | 70.6 Million USD | 76.06% |
| 1993 Q1 | 21.4 Million USD | 0.94% |
| 1993 Q2 | 16.1 Million USD | -24.77% |
| 1992 Q3 | 16.7 Million USD | 46.49% |
| 1992 Q1 | 12.3 Million USD | 19.42% |
| 1992 FY | 40.1 Million USD | 22.63% |
| 1992 Q2 | 11.4 Million USD | -7.32% |
| 1992 Q4 | 21.2 Million USD | 26.95% |
| 1991 Q3 | 8.7 Million USD | 1.16% |
| 1991 Q1 | 9.3 Million USD | 13.41% |
| 1991 Q4 | 10.3 Million USD | 18.39% |
| 1991 FY | 32.7 Million USD | 24.81% |
| 1991 Q2 | 8.6 Million USD | -7.53% |
| 1990 Q2 | 7.5 Million USD | -22.68% |
| 1990 FY | 26.2 Million USD | 43.17% |
| 1990 Q4 | 8.2 Million USD | 6.49% |
| 1990 Q1 | 9.7 Million USD | 18.29% |
| 1990 Q3 | 7.7 Million USD | 2.67% |
| 1989 Q2 | 3.8 Million USD | 0.0% |
| 1989 FY | 18.3 Million USD | -27.38% |
| 1989 Q1 | - USD | 0.0% |
| 1989 Q4 | 8.2 Million USD | 78.26% |
| 1989 Q3 | 4.6 Million USD | 21.05% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | -13.592% |
| Embecta Corp. | 70.4 Million USD | 22.301% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | -191.283% |
| Dynavax Technologies Corporation | -6.38 Million USD | 956.159% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 126.141% |
| Pacira BioSciences, Inc. | 41.95 Million USD | -30.378% |
| PainReform Ltd. | -9.34 Million USD | 685.402% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 795.044% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 1313.925% |
| SCYNEXIS, Inc. | 67.04 Million USD | 18.408% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 1865.352% |
| Cosmos Health Inc. | -18.54 Million USD | 394.996% |
| Journey Medical Corporation | -3.85 Million USD | 1519.673% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 1313.925% |
| Safety Shot Inc | -15.08 Million USD | 462.659% |
| Alpha Teknova, Inc. | -36.78 Million USD | 248.722% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 139.163% |
| Bright Green Corporation | -13.12 Million USD | 516.678% |
| Procaps Group, S.A. | 42.54 Million USD | -28.585% |
| Theratechnologies Inc. | -23.95 Million USD | 328.326% |
| Harrow Health, Inc. | -24.41 Million USD | 324.079% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 1231.334% |
| Biofrontera Inc. | -20.13 Million USD | 371.72% |
| DURECT Corporation | -27.62 Million USD | 298.016% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -4056.535% |
| Cronos Group Inc. | -73.96 Million USD | 173.956% |
| OptiNose, Inc. | -35.48 Million USD | 254.158% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 105.458% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 229.624% |
| RedHill Biopharma Ltd. | 23.91 Million USD | -128.717% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -1006.168% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -34513.024% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 971.113% |
| Radius Health, Inc. | -25.79 Million USD | 312.089% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 987.546% |
| ProPhase Labs, Inc. | -16.78 Million USD | 425.944% |
| Phibro Animal Health Corporation | 2.41 Million USD | -2164.073% |
| Procaps Group S.A. | 42.54 Million USD | -28.585% |
| Alvotech | -551.73 Million USD | 109.914% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 632.205% |
| Rockwell Medical, Inc. | -8.43 Million USD | 748.181% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 445.241% |
| SIGA Technologies, Inc. | 68.06 Million USD | 19.64% |
| Tilray Brands, Inc. | -244.98 Million USD | 122.328% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -355.34% |
| Shineco, Inc. | -22.44 Million USD | 343.663% |
| PetIQ, Inc. | 2.13 Million USD | -2466.87% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 1371.55% |
| Incannex Healthcare Limited | -18.45 Million USD | 396.332% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 78.094% |
| Alimera Sciences, Inc. | -20.13 Million USD | 371.707% |
| Silver Spike Investment Corp. | 7.34 Million USD | -645.221% |
| Assertio Holdings, Inc. | -331.94 Million USD | 116.479% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 929.703% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 770.081% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 405.604% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 372.719% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 134.129% |
| Hempacco Co., Inc. | -13.12 Million USD | 516.728% |
| Talphera, Inc. | -18.39 Million USD | 397.331% |
| Alvotech | -551.73 Million USD | 109.914% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | -53.471% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 83.255% |
| Currenc Group, Inc. | -15.3 Million USD | 457.363% |
| Kamada Ltd. | 8.28 Million USD | -560.309% |
| Indivior PLC | 2 Million USD | -2635.0% |
| Evoke Pharma, Inc. | -7.79 Million USD | 801.975% |
| Flora Growth Corp. | -57.03 Million USD | 195.904% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 372.719% |
| Evolus, Inc. | -61.68 Million USD | 188.676% |
| HUTCHMED (China) Limited | 100.78 Million USD | 45.723% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 60.231% |
| Akanda Corp. | -32.27 Million USD | 269.481% |